Active surveillance is a management strategy for low-risk prostate cancer that replaces immediate surgery or radiation with regular monitoring. The goal is to track the cancer closely and move to treatment only if it shows signs of becoming more aggressive. For men with slow-growing prostate cancer, this approach preserves quality of life while keeping the window open for a cure if the disease changes. At 10 years, cancer-specific survival for men on active surveillance is effectively 100%, based on long-term data from Memorial Sloan Kettering Cancer Center.
How It Differs From Watchful Waiting
Active surveillance and watchful waiting are both “conservative” approaches, but they have very different goals. Active surveillance involves structured, scheduled testing with the intent to treat the cancer if it progresses. You’re not ignoring the cancer. You’re watching it with a plan to act. Watchful waiting, by contrast, skips routine testing and only addresses symptoms if advanced cancer develops later. It’s typically chosen by older men or those with other serious health conditions where the risks of treatment outweigh the benefits.
The distinction matters because active surveillance is designed to preserve the opportunity for curative treatment. Watchful waiting accepts that cure isn’t the priority. Your age, overall health, and the cancer’s characteristics all factor into which approach makes sense.
Who Qualifies for Active Surveillance
Active surveillance is primarily offered to men with low-risk prostate cancer, defined as a Gleason score of 6 or lower and a PSA level of 10 ng/mL or less. Some programs also include men with favorable intermediate-risk disease, meaning a Gleason score of 3+4 or a PSA between 10 and 20 ng/mL, particularly if they have other health conditions and a life expectancy under 10 years.
Certain factors can tip the decision away from surveillance even when the cancer appears low-risk. A high PSA density (elevated PSA relative to prostate size), three or more positive biopsy cores, a high-risk result on genomic testing, or a known BRCA2 gene mutation may favor upfront treatment instead. These decisions are made collaboratively between you and your care team, weighing the specific characteristics of your cancer against the potential side effects of treatment.
The Monitoring Schedule
Active surveillance follows a structured testing schedule with four main components: PSA blood tests, digital rectal exams, prostate MRI scans, and repeat biopsies. A typical schedule looks like this:
- PSA blood test: Every 6 months. This tracks changes in a protein produced by the prostate that can signal cancer growth.
- Digital rectal exam: During regular surveillance visits, to check for physical changes in the prostate.
- Prostate MRI: Roughly every 18 months. This imaging can detect changes in tumor size or new suspicious areas.
- Prostate biopsy: Every 3 years. Tissue samples are examined under a microscope to check whether the cancer’s grade has changed.
Some programs use slightly different intervals. The Johns Hopkins protocol, for example, historically used PSA testing every 6 months with yearly biopsies. Another widely used protocol (called PRIAS) spaces biopsies further apart: at years 1, 3, 7, and 10, then every 5 years. Biopsies are generally discontinued around age 75. Your specific schedule will depend on your institution’s protocol and how your cancer behaves over time.
The Role of MRI in Surveillance
Multiparametric MRI has become an increasingly important part of active surveillance. The European Association of Urology recommends an MRI before a confirmatory biopsy, which usually happens within the first year of diagnosis. If the MRI finds a suspicious area, targeted biopsy samples are taken from that spot in addition to the standard systematic biopsy.
After the first year, MRI is especially useful for its ability to rule out aggressive cancer. A negative MRI result correctly identifies the absence of significant cancer up to 93% of the time. When combined with other markers like PSA density, that accuracy improves further. MRI results can also adjust your monitoring timeline. If your initial MRI is clean, follow-up scans may be spaced to every 2 to 3 years. If it shows a suspicious area that the biopsy didn’t confirm as dangerous, you’ll likely be rechecked in 1 to 2 years with a closer watch for changes.
One limitation: MRI-guided targeted biopsy alone may miss some progression that standard systematic biopsy catches. In one study, only 3% of cancers showed grade progression on MRI-targeted biopsy compared to 27% detected by systematic biopsy. This is why most programs still use both approaches together rather than relying on MRI alone.
Genomic Testing and Risk Assessment
Genomic classifiers are lab tests run on biopsy tissue that estimate how aggressive your specific cancer is at a molecular level. These tests provide information beyond what a Gleason score and PSA can tell you. They help predict outcomes like the chance of finding more aggressive cancer at surgery or the likelihood of the cancer recurring after treatment.
For men considering active surveillance, a low genomic risk score can provide reassurance that monitoring is a safe choice. A high score, on the other hand, might identify someone whose cancer looks low-risk on standard measures but carries hidden molecular features that make early treatment a better option. These tests are increasingly used as part of the decision-making process, helping reduce both overtreatment of harmless cancers and undertreatment of deceptively dangerous ones.
What Triggers a Switch to Treatment
The most common reason men move from surveillance to active treatment is a change in the cancer’s grade on biopsy, called histopathological progression. This means the cancer cells look more aggressive under the microscope than they did at diagnosis. In a study tracking men from 2015 to 2020, biopsy-detected progression was by far the strongest trigger for starting treatment.
MRI progression, where imaging shows significant growth or new suspicious areas, has also become an important trigger, particularly since MRI became a routine part of surveillance protocols. Rising PSA levels play a smaller role and are generally less reliable on their own as a reason to switch.
Notably, about 27% of men who transitioned to treatment between 2015 and 2020 did so without a clear clinical trigger, suggesting that anxiety or personal preference still plays a role in the decision. This highlights the psychological dimension of surveillance: living with untreated cancer, even slow-growing cancer, can be challenging for some men.
Long-Term Outcomes
The survival data for active surveillance is reassuring. In the Memorial Sloan Kettering cohort, 10-year prostate cancer-specific survival was 100%. The probability of the cancer spreading to other parts of the body was just 0.6% at 10 years and 1.5% at 15 years.
Grade progression does happen over time. About 24% of men with the lowest-grade cancers (Grade Group 1) see their cancer reclassified to a higher grade within 5 years, 36% by 10 years, and 41% by 15 years. When that happens, curative treatment with surgery or radiation is still possible. The key insight is that active surveillance delays treatment, not eliminates it. Roughly 4 in 10 men will eventually need treatment, but the rest avoid it entirely, along with its side effects.
Quality of Life Considerations
The primary advantage of active surveillance over immediate surgery or radiation is avoiding treatment-related side effects. Surgery and radiation for prostate cancer frequently cause sexual dysfunction, urinary incontinence, and bowel problems. These complications can be long-lasting and significantly affect daily life. By deferring treatment, men on surveillance maintain their baseline function for as long as the cancer remains stable, which for many men is years or even permanently.
The tradeoff is psychological. Some men find it difficult to live with a known cancer diagnosis without treating it. The periodic biopsies and PSA tests can cause anxiety, and the possibility of progression is always in the background. For most men with low-risk disease, the data strongly supports surveillance as a safe strategy, but comfort with that approach varies from person to person.